N-cyclopentyl-3,3-dimethylbutanamide

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: N-cyclopentyl-3,3-dimethylbutanamide
• 化学式: C₁₁H₂₁NO
• mdl: MFCD02860371
• 分子量: 183.29
• InChiKey: WDFHMIVFWSIGNV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.909
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• SULFONYL CONTAINING BENZOTHIAZOLE INHIBITORS OF ENDOTHELIAL LIPASE
  申请人：Bristol-Myers Squibb Company

  公开号：US20140011799A1

  公开（公告）日：2014-01-09

  The present invention provides compounds of Formula (I): as defined in the specification and compositions comprising any of such novel compounds. These compounds are endothelial lipase inhibitors which may be used as medicaments.

  本发明提供了公式(I)的化合物：如规范中所定义的和包含任何此类新化合物的组合物。这些化合物是内皮细胞脂肪酶抑制剂，可用作药物。
• NOVEL HETEROCYCLIC COMPOUNDS
  申请人：Jain Rajesh

  公开号：US20100311732A1

  公开（公告）日：2010-12-09

  The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers including R and S isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention also provides pharmaceutical compositions comprising compounds of Formula I and methods of treating or preventing one or more conditions that may be regulated or normalized via inhibition of dipeptidyl peptidase IV (DPP-IV).

  本发明涉及一种新型I式化合物，其药学上可接受的衍生物、互变异构体、立体异构体（包括R和S异构体）、多晶形、前药、代谢物、盐或溶剂化物。本发明还涉及制备新型I式化合物、其药学上可接受的衍生物、互变异构体、立体异构体、多晶形、前药、代谢物、盐或溶剂化物的方法。本发明还提供了包含I式化合物的制药组合物和通过抑制二肽基肽酶IV（DPP-IV）来治疗或预防可能通过调节或规范的一种或多种情况的方法。
• SUBSTITUTED 1H-IMIDAZO[4,5-b]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：US20180125826A1

  公开（公告）日：2018-05-10

  Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones as NR2B receptor ligands. Such compounds may be used in NR2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by NR2B receptor activity.
• US8163763B2
  申请人：——

  公开号：US8163763B2

  公开（公告）日：2012-04-24
• US8455479B2
  申请人：——

  公开号：US8455479B2

  公开（公告）日：2013-06-04